Inclusion Criteria:

- NSCLC, locally advanced (stage IIIB) or metastatic (stage IV) disease, not amenable
to curative surgery or radiotherapy

- Female or male patients aged 70 years and over

- Measurable disease according to RECIST criteria, with at least one measurable lesion

- No prior chemotherapy, biological or immunological therapy

- Adeguate hepatic, renal and bone marrow function

- ECOG Performance Status ≤ 2

- Life expectancy of at least 12 weeks

Exclusion Criteria:

- Newly diagnosed CNS metastases that have not been treated with surgery or radiation

- Less than 4 weeks since completion of prior radiotherapy or persistence of any
radiotherapy related toxicity

- Any other experimental or anti-cancer therapy within 30 days before study drug
administration

- Concurrent treatment with any other experimental or anti-cancer therapy